Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group. Pasnoor M, et al. Among authors: swenson a. Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15. Neurology. 2016. PMID: 27306628 Free PMC article. Clinical Trial.
Phase II trial of methotrexate in myasthenia gravis.
Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ; Muscle Study Group. Pasnoor M, et al. Ann N Y Acad Sci. 2012 Dec;1275(1):23-8. doi: 10.1111/j.1749-6632.2012.06804.x. Ann N Y Acad Sci. 2012. PMID: 23278574 Free PMC article. Clinical Trial.
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Cudkowicz ME, et al. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Lancet Neurol. 2013. PMID: 24067398 Clinical Trial.
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.
Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, Simpson E, Genge A, Bertorini T, Fernandes JA, Swenson A, Elman L, Dimachkie M, Herbelin L, Miller J, Lu J, Wilkins H, Swerdlow RH, Statland J, Barohn R; Western ALS (WALS) Rasagiline Study Group. Macchi Z, et al. Among authors: swenson a. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):345-52. doi: 10.3109/21678421.2015.1026826. Epub 2015 Apr 2. Amyotroph Lateral Scler Frontotemporal Degener. 2015. PMID: 25832828 Free PMC article.
Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.
Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS. Murphy J, et al. Among authors: swenson aj. Neurology. 2016 Mar 1;86(9):813-20. doi: 10.1212/WNL.0000000000002305. Epub 2016 Jan 22. Neurology. 2016. PMID: 26802094 Free PMC article.
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME; Mexiletine ALS Study Group. Weiss MD, et al. Among authors: swenson a. Neurology. 2016 Apr 19;86(16):1474-81. doi: 10.1212/WNL.0000000000002507. Epub 2016 Feb 24. Neurology. 2016. PMID: 26911633 Free PMC article. Clinical Trial.
Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients.
Woolley S, Goetz R, Factor-Litvak P, Murphy J, Hupf J, Garofalo DC, Lomen-Hoerth C, Andrews H, Heitzman D, Bedlack R, Katz J, Barohn R, Sorenson E, Oskarsson B, Filho AF, Kasarskis E, Mozaffar T, Nations S, Swenson A, Koczon-Jaremko A, Christodoulou G, Mitsumoto H. Woolley S, et al. Among authors: swenson a. Behav Neurol. 2018 Oct 31;2018:5969137. doi: 10.1155/2018/5969137. eCollection 2018. Behav Neurol. 2018. PMID: 30515252 Free PMC article.
Corrigendum to "Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients".
Woolley S, Goetz R, Factor-Litvak P, Murphy J, Hupf J, Garofalo DC, Lomen-Hoerth C, Andrews H, Heitzman D, Bedlack R, Katz J, Barohn R, Sorenson E, Oskarsson B, Filho AF, Kasarskis E, Mozaffar T, Nations S, Swenson A, Koczon-Jaremko A, Christodoulou G, Mitsumoto H. Woolley S, et al. Among authors: swenson a. Behav Neurol. 2019 Dec 4;2019:6704740. doi: 10.1155/2019/6704740. eCollection 2019. Behav Neurol. 2019. PMID: 31885727 Free PMC article.
Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.
Mitsumoto H, Garofalo DC, Santella RM, Sorenson EJ, Oskarsson B, Fernandes JAM Jr, Andrews H, Hupf J, Gilmore M, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Nations SP, Swenson AJ, Factor-Litvak P. Mitsumoto H, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2020 May;21(3-4):263-272. doi: 10.1080/21678421.2020.1746810. Epub 2020 Apr 10. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 32276554 Free PMC article.
131 results